NCT01896323View on ClinicalTrials.gov

CC-223 and Ketoconazole Drug-Drug Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 1, 2013

Primary Completion Date

August 1, 2013

Study Completion Date

August 1, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

CC-223

CC-223 20 mg tablets

DRUG

Ketoconazole

Ketoconazole 400 mg tablets

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01896323 - CC-223 and Ketoconazole Drug-Drug Interaction Study | Biotech Hunter | Biotech Hunter